An et al., 2025 - Google Patents
Generation of orthotopic intracranial glioblastoma patient-derived xenograft models: insights into extrachromosomal DNA-driven MYC (N) and PDGFRA oncogene …An et al., 2025
View HTML- Document ID
- 443991714683645361
- Author
- An S
- Lim J
- Kim Y
- Shim A
- Han T
- Kim H
- Park S
- Kim Y
- Moon K
- Kim I
- Jung S
- Lee C
- Lee K
- Park A
- Jung T
- et al.
- Publication year
- Publication venue
- Neoplasia
External Links
Snippet
Background This study aimed to establish orthotopic intracranial patient-derived xenograft (PDX) models to investigate molecular and pathological features and to evaluate potential preclinical therapeutic approaches in glioblastoma (GBM). Methods Fresh or cryopreserved …
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis | |
| Davies et al. | An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer | |
| Venturutti et al. | TBL1XR1 mutations drive extranodal lymphoma by inducing a pro-tumorigenic memory fate | |
| Saqcena et al. | SWI/SNF complex mutations promote thyroid tumor progression and insensitivity to redifferentiation therapies | |
| Mei et al. | Cellular models of development of ovarian high‐grade serous carcinoma: A review of cell of origin and mechanisms of carcinogenesis | |
| Jiao et al. | Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells | |
| Lee et al. | Patient-derived xenografts from non–small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy | |
| Liao et al. | Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells | |
| Green et al. | Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma | |
| Navarro et al. | PARP-1/PARP-2 double deficiency in mouse T cells results in faulty immune responses and T lymphomas | |
| Frank et al. | Recent advances in prostate cancer research: Large-scale genomic analyses reveal novel driver mutations and DNA repair defects | |
| Collins et al. | Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target | |
| Gachet et al. | Deletion 6q drives T-cell leukemia progression by ribosome modulation | |
| Gudjonsson et al. | Stem cell biology and the cellular pathways of carcinogenesis | |
| Duan et al. | Integrated analyses of multi-omic data derived from paired primary lung cancer and brain metastasis reveal the metabolic vulnerability as a novel therapeutic target | |
| Qian et al. | The role of RANKL and MMP‐9 in the bone resorption caused by ameloblastoma | |
| Kato et al. | Precision modeling of gall bladder cancer patients in mice based on orthotopic implantation of organoid-derived tumor buds | |
| Pulver et al. | A BRCA1 coiled-coil domain variant disrupting PALB2 interaction promotes the development of mammary tumors and confers a targetable defect in homologous recombination repair | |
| JP2023505726A (en) | Methods of obtaining nucleic acids for sequencing | |
| Tang et al. | Androgen deprivation and stem cell markers in prostate cancers | |
| Haffner et al. | Phenotypic characterization of two novel cell line models of castration‐resistant prostate cancer | |
| Yamaguchi et al. | Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model | |
| Lang et al. | Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies | |
| Van Emmenis et al. | The identification of CELSR3 and other potential cell surface targets in neuroendocrine prostate cancer | |
| Sun et al. | Blocking WNT7A enhances MHC-I antigen presentation and enhances the effectiveness of immune checkpoint blockade therapy |